# Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesi…

> PubMed lists PMID 32700442 in Diabetes, obesity & metabolism as Journal Article, Research Support, Non-U.S. Gov't, Systematic Review, Network Meta-Analysis, with publication-date metadata of 2020-09-03 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32700442-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32700442-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-32700442-lixisenatide-v1.json
- Content SHA-256: `01e13d787d20fd99531109a95f769a4d0f9cc05e49961686bbd6d6889b7f703c`

## Claims and source pins

### Headline

Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesi… ([`pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57`](#source-pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57))

### Summary

PubMed lists PMID 32700442 in Diabetes, obesity & metabolism as Journal Article, Research Support, Non-U.S. Gov't, Systematic Review, Network Meta-Analysis, with publication-date metadata of 2020-09-03 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57`](#source-pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57))

### Paragraph 1

PubMed lists PMID 32700442 in Diabetes, obesity & metabolism as Journal Article, Research Support, Non-U.S. Gov't, Systematic Review, Network Meta-Analysis, with publication-date metadata of 2020-09-03 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57`](#source-pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57`](#source-pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57))

## Sources

<a id="source-pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57"></a>
- **Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis. · retained source version 1:2026-01-27:current:d7247fdd4d57938d859f9e82d712bb1f0bc5b45402267f72631cdabf3db6ccb6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32700442/) (`pubmed-observation-pmid-32700442-2026-01-27-d7247fdd4d57`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesi…." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-32700442-lixisenatide-v1.json SHA-256: 01e13d787d20fd99531109a95f769a4d0f9cc05e49961686bbd6d6889b7f703c.